Please login to the form below

Not currently logged in
Email:
Password:

Amgen promotes Michael Severino to chief medical officer

He will also take over senior VP global development role from Sean Harper, who is promoted to executive VP, R&D

Michael Severino has been promoted to the dual role of senior VP, global development and corporate chief medical officer at Amgen.

The former VP of global development, Severino will take over from Sean Harper who has been appointed executive VP, R&D at the US biotech.

Harper's appointment was announced in December, 2011, at the same time as CEO Kevin Sharer declared his intention to step down this May.

Severino has spent eight years at Amgen, where he also served as senior director of inflammation early development and head of the company's proof-of-concept group within medical sciences.

His previous experience includes several years at Merck Research Laboratories working across a wide range of therapeutic areas including vaccines, oncology, diabetes and neurosciences.

"Since joining Amgen in 2004, Mike has demonstrated leadership across Amgen's global development organisation and has made significant contributions to the overall advancement of Amgen's pipeline," said Harper.

"Mike brings broad experience and immense expertise to his new role and I am confident that under his leadership, Amgen's global development team will continue to deliver important new medicines for patients with serious illnesses."

Harper joined Amgen in 2002 as vice president of development, and during his time at the company established its medical sciences capability to focus on translational medicine research.

Like Severino, he also has previous experience at Merck Research Laboratories. He is also a member of the PhRMA Regulatory Affairs Coordinating Committee.

16th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics